Daily Ards Research Analysis
Analyzed 4 papers and selected 3 impactful papers.
Summary
Analyzed 4 papers and selected 3 impactful articles.
Selected Articles
1. Unraveling the Link: A Systematic Review and Meta analysis of Acute Respiratory Distress Syndrome and Delirium.
This registered systematic review/meta-analysis pooled 13 studies (10,052 ARDS patients) and found delirium prevalence of 41% (substantial heterogeneity). Delirium associated with longer ICU stay and ventilation; pooled RR versus controls was elevated but not statistically significant. Authors recommend multidisciplinary prevention strategies.
Impact: Provides quantitative synthesis of delirium burden in ARDS with large pooled sample and registered protocol, informing ICU management and research priorities for cognitive outcomes.
Clinical Implications: Clinicians should recognize high delirium prevalence in ARDS, prioritize sedation minimization, early mobilization, delirium monitoring and interdisciplinary management to potentially shorten ICU stay and ventilation duration.
Key Findings
- Pooled delirium prevalence in ARDS patients was 41% (95% CI 23%-58%) across 13 studies (n=10,052).
- Delirium in ARDS consistently associated with longer ICU length of stay and prolonged mechanical ventilation.
- Pooled relative risk for delirium compared with controls was elevated (RR 1.34) but not statistically significant, with substantial heterogeneity.
Methodological Strengths
- PROSPERO registration and systematic search across multiple databases up to Sep 2024.
- Large pooled sample (10,052 patients) and use of random-effects models with bias assessment (RoB2/ROBINS-I).
Limitations
- Substantial heterogeneity across included studies limits precision of pooled estimates.
- Included studies varied in delirium definitions, assessment methods and ARDS severity, limiting causal inference.
Future Directions: Prospective multicenter studies with standardized delirium assessments in ARDS, and trials testing targeted prevention (sedation protocols, mobilization, delirium bundles) with cognitive outcomes are needed.
BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is a critical condition characterized by severe hypoxemia and pulmonary edema, often resulting from pneumonia, sepsis, trauma, or aspiration. It affects 10-15% of ICU patients and is associated with high mortality rates (30-40%). Delirium, an acute cognitive impairment, is prevalent in critically ill patients, particularly in the ICU, and correlates with adverse outcomes. OBJECTIVE: This systematic review and meta-analysis aim to summarize the current evidence regarding the relationship between ARDS and delirium, focusing on the prevalence of delirium in ARDS patients, its impact on delirium development and mortality, potential correlations between the two conditions, and their clinical outcomes. METHODS: A systematic search was conducted across PubMed, Scopus, and Web of Science from inception until September 2024, leading to the identification of 838 records. Pooled risk ratios and prevalence were calculated using a random-effects model. The risk of bias was assessed using the revised Cochrane risk of bias tool for randomized trials (RoB2) and Risk of Bias in non-randomized studies of interventions (ROBINS-I) tool. RESULTS: Thirteen studies involving 10,052 patients with ARDS were included. The pooled prevalence of delirium among ARDS patients was 41% (95% CI: 23%-58%), with substantial heterogeneity. Meta-analysis showed a higher risk of delirium among ARDS patients compared with controls; however, this association was not statistically significant (RR 1.34, 95% CI: 0.63-2.83). No statistically significant associations were observed between delirium and comorbid depression or anxiety. Delirium in ARDS patients was consistently associated with prolonged ICU stay, longer mechanical ventilation, and adverse clinical outcomes. CONCLUSION: Patients with ARDS frequently experience delirium, resulting in extended ICU admissions, prolonged mechanical ventilation, and cognitive impairment. Hypoxia, inflammation, sedation, and psychological factors contributes to delirium risk in ARDS patients. A multidisciplinary approach incorporating sedative minimization, early mobilization, and psychological support may mitigate delirium and improve patient outcomes. PROSPERO REGISTRATION NUMBER: (CRD42024564895): https://www.crd.york.ac.uk/PROSPERO/view/CRD42024564895.
2. Bioreactor-derived EVs from placental MSCs show context- and donor-specific immunomodulatory trends in human 3D lung inflammatory models.
This translational study combined GMP-compliant 3D bioreactor EV production with 3D human airway models (CF and ARDS). 3D culture increased EV yield. EV and parental hPSC activities were donor- and context-dependent; EVs induced consistent macrophage IL-10 and Arginase-1 upregulation, but immune/epithelial responses diverged, indicating EVs are distinct functional entities.
Impact: Offers a translational framework linking scalable GMP EV manufacturing with functionally relevant human 3D ARDS models and highlights donor/context variability—critical for clinical translation of MSC-EV therapies.
Clinical Implications: Before clinical use of placental-MSC EVs for ARDS, donor selection and functional profiling in disease-relevant human models are necessary; manufacturing in 3D bioreactors can increase yield without compromising EV quality.
Key Findings
- 3D stirred-tank microcarrier culture increased EV yield compared with 2D while maintaining quality.
- Substantial donor-dependent variability in hPSC and EV immunomodulatory activity translated into model- and compartment-specific responses.
- EVs consistently induced macrophage IL-10 and Arginase-1 (up to 25-fold), but did not simply replicate parental cell cytokine profiles.
Methodological Strengths
- Integration of scalable GMP-compliant 3D bioreactor EV production with advanced human 3D airway models (Epithelix SmallAir™).
- Comprehensive EV characterization (fNTA, flow cytometry, protein content) and functional assays across immune and epithelial compartments.
Limitations
- Preclinical/translational in vitro models only; in vivo efficacy and safety not assessed.
- Substantial donor heterogeneity implies larger donor cohorts are needed to identify consistent therapeutic candidates.
Future Directions: Expand donor cohorts, validate findings in in vivo ARDS models, define functional potency assays for EV release criteria, and initiate early-phase safety/biomarker-guided clinical trials.
BACKGROUND: Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) have garnered attention as cell-free therapeutics due to their regenerative and immunomodulatory potential. Human placenta-derived stromal cells (hPSCs) are a particularly promising source owing to their accessibility, scalability, and superior proliferative capacity-yet the functional behavior of their EVs, especially in inflammatory disease contexts, remains poorly defined. This study introduces a novel integrated approach, combining a 3D microcarrier bioreactor for scalable EV production with advanced 3D human airway disease models, to resolve how donor variability and inflammatory context shape the immunomodulatory activity of hPSC-EVs. METHODS: hPSCs were expanded under Good Manufacturing Practice (GMP)-compliant conditions in both conventional 2D cultures and 3D stirred-tank bioreactors using microcarrier technology. EVs were isolated from conditioned media via tangential flow filtration and characterized by fluorescent nanoparticle tracking analysis (fNTA), flow cytometry and protein content. Functional effects of hPSCs and EVs were assessed in PBMC co-cultures and two human 3D airway models-cystic fibrosis (CF) and acute respiratory distress syndrome (ARDS)-based on the Epithelix SmallAir™ platform, integrating primary airway epithelium and macrophages at the air-liquid interface. Inflammation was induced with TNF-α (CF) or LPS (ARDS), and EVs or hPSCs were administered to both apical and basal compartments. RESULTS: 3D culture significantly increased EV yield without compromising quality. A key finding was a substantial donor-dependent variability in both hPSC and EV activity, which translated into distinct, model-specific immunomodulatory profiles. Notably, EV- and hPSC-mediated responses diverged across immune and epithelial compartments, indicating that EVs do not simply recapitulate parental cell function. In the 3D models, despite substantial heterogeneity, induction of IL-10 and Arginase-1 (up to 25-fold) in the macrophage compartment emerged as a consistent trend across experimental conditions. In contrast, parental hPSCs showed broader but less predictable cytokine modulation, including variable TNF-α suppression and context-specific effects across donors. CONCLUSIONS: Our findings demonstrate that hPSC- and EV-mediated immunomodulation is highly context-dependent and cannot be predicted solely from donor identity or culture format. Rather than identifying a single optimal condition, this study highlights the need for larger donor cohorts and functional profiling in advanced human models and supports the use of EVs as distinct, cell-free immunomodulatory entities with compartment-specific activity. Together, this work provides a translational framework linking GMP-compliant EV manufacturing with functionally relevant human disease modeling.
3. Aerosol therapy during noninvasive ventilation (NIV) and nasal high-flow therapy (HFT): current technology and consensus-based recommendations.
An interdisciplinary expert panel performed a systematic literature search and produced consensus recommendations for aerosol delivery during NIV and nasal high-flow therapy. Key recommendation: vibrating mesh nebulizers (VMNs) provide superior lung deposition versus jet nebulizers; JNs remain acceptable in specific situations (viscous solutions, resource limits).
Impact: Provides practical, consensus-based technical recommendations for aerosol delivery during NIV/HFT—directly relevant to bedside respiratory management and device selection.
Clinical Implications: Clinicians and respiratory therapists should preferentially use VMNs for aerosol delivery during NIV and HFT when available; select JNs only when VMNs are unavailable, for viscous solutions, or due to budget constraints, and tailor device choice to patient and technical context.
Key Findings
- VMNs achieve better lung deposition than jet nebulizers during NIV and HFT in reviewed studies/technical reports.
- JN remains a pragmatic alternative when VMN unavailable, for highly viscous drug solutions, or when cost/resources limit VMN use.
- Device selection should be individualized considering indication, patient factors, and technical/economic constraints.
Methodological Strengths
- Interdisciplinary expert panel and multi-stage consensus process informed by systematic PubMed search up to Nov 2025.
- Included clinical studies, reviews, guideline documents and technical reports with evaluation of evidence levels.
Limitations
- Consensus-based recommendations may lack the strength of formal guideline processes and are reliant on available heterogeneous evidence and technical reports.
- Some recommendations are based on technical deposition data rather than randomized clinical outcome trials of clinical endpoints.
Future Directions: Randomized or pragmatic clinical trials comparing VMN versus JN during NIV/HFT with patient-centered outcomes (drug effect, ventilation duration, aerosol-related adverse events) are needed to strengthen evidence.
BACKGROUND: Aerosol therapy is an essential procedure in the treatment of acute and chronic respiratory diseases. Currently, there are no up-to-date guidelines from German-speaking countries on the selection and use of nebulizer systems in patients undergoing high-flow therapy via nasal cannula (HFT) and non-invasive ventilation (NIV). METHODS: An interdisciplinary panel of experts consisting of pulmonologists and intensive care physicians developed practice-oriented recommendations for aerosol therapy under HFT and NIV. The evidence base was derived from a systematic search of the PubMed database of the US National Library of Medicine up to and including November 2025.Publications on clinical studies, reviews, guideline documents, and technical reports were included. The respective level of evidence of the information was evaluated. The recommendations were agreed upon in a multi-stage process. RESULTS: Aerosol administration under HFT and NIV with a vibrating mesh nebulizer (VMN) achieved better lung deposition compared to the use of a jet nebulizer (JN). A JN is suitable if VMNs are not available, if highly viscous drug solutions are to be nebulized, or if there are budgetary limitations. CONCLUSION: The choice and application of the nebulizer system should be patient-specific, consistent with the indication, taking into account technical, clinical, and economic requirements. Die Aerosoltherapie ist ein essenzielles Verfahren in der Behandlung akuter und chronischer Atemwegserkrankungen. Derzeit existiert keine aktuelle Leitlinie aus den deutschsprachigen Ländern zur Auswahl und Anwendung von Verneblersystemen bei Patienten unter High-Flow-Therapie via Nasenkanüle (HFT) und nichtinvasiver Beatmung (NIV).Ein interdisziplinäres Expertengremium aus Pneumologen und Intensivmedizinern entwickelte praxisorientierte Empfehlungen zur Aerosoltherapie unter HFT und NIV. Die Evidenzgrundlage bildete eine systematische Recherche in der Datenbank PubMed der US National Library of Medicine bis einschließlich November 2025.Einbezogen wurden Publikationen zu klinischen Studien, Übersichtsarbeiten, Leitliniendokumente und technische Berichte. Der jeweilige Evidenzgrad der Informationen wurde bewertet. Die Empfehlungen wurden in einem Mehrstufenverfahren konsentiert.Die Aerosolapplikation unter HFT und NIV mit einem Vibrating-Mesh-Vernebler (VMN) führt zu einer besseren Lungendeposition im Vergleich zur Verwendung eines Jet Nebulizers (JN). Ein JN ist geeignet, wenn VMN nicht verfügbar sind, hochvisköse Medikamentenlösungen vernebelt werden sollen oder wenn budgetäre Limitationen bestehen.Die Wahl und Anwendung des Verneblersystems sollte patientenindividuell, indikationsbezogen und unter Berücksichtigung technischer, klinischer und ökonomischer Rahmenbedingungen erfolgen.